T-cell-independent antitumor effects of CD40 ligation

International Reviews of Immunology

Volumn 31, Issue 4, 2012, Pages 267-278

  Rakhmilevich, Alexander L ^a   Alderson, Kory L ^a   Sondel, Paul M ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Anti CD40; Macrophages; NK cells

Indexed keywords

CD40 ANTIGEN; CD40 MONOCLONAL ANTIBODY; CPG OLIGODEOXYNUCLEOTIDE; CYCLOPHOSPHAMIDE; DACETUZUMAB; DOXORUBICIN; GEMCITABINE; MONOCLONAL ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EFFECTOR CELL; HUMAN; INNATE IMMUNITY; MACROPHAGE; MELANOMA; NATURAL KILLER CELL; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; KILLER CELLS, NATURAL; MACROPHAGES; MICE; NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84863925220     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2012.698337     Document Type: Article

References (89)

1. Ma DY, Clark EA. The role of CD40 and CD154/CD40L in dendritic cells. Semin Immunol. 2009;21(5):265-272.
2. Bennett SR, Carbone FR, Karamalis F, et al. Help for cytotoxic-T-cell responses ismediated by CD40 signalling. Nature. 1998;393(6684):478-480.
3. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature. 1998;393(6684):474-478.
4. Schoenberger SP, Toes RE, van der Voort EI, et al. T-cell help for cytotoxic T lymphocytes ismediated by CD40-CD40L interactions. Nature. 1998;393(6684):480-483.
5. Sotomayor EM, Borrello I, Tubb E, et al. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. NatMed. 1999;5(7):780-787. (Pubitemid 29318612)
6. MackeyMF, Gunn JR, Ting PP, et al. Protective immunity induced by tumor vaccines requires interaction between CD40 and its ligand, CD154. Cancer Res. 1997;57(13):2569-2574. (Pubitemid 27283758)
7. Diehl L, den Boer AT, Schoenberger SP, et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med. 1999;5(7):774-779. (Pubitemid 29318611)
8. Fonsatti E,MaioM,AltomonteM,et al.Biology and clinical applications ofCD40in cancer treatment. Semin Oncol. 2010;37(5):517-523.
9. French RR, Chan HT, Tutt AL, et al. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. NatMed. 1999;5(5):548-553. (Pubitemid 29220214)
10. Gurunathan S, Irvine KR,WuCY, et al.CD40 ligand/trimerDNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge. J Immunol. 1998;161(9):4563-4571. (Pubitemid 28492028)
11. Nakajima A, Kodama T, Morimoto S, et al. Antitumor effect of CD40 ligand: elicitation of local and systemic antitumor responses by IL-12 and B7. J Immunol. 1998;161(4):1901-1907. (Pubitemid 28387612)
12. Khalil M, Vonderheide RH. Anti-CD40 agonist antibodies: preclinical and clinical experience. Update Cancer Ther. 2007;2(2):61-65. (Pubitemid 47393664)
13. Tai YT, Li X, Tong X, et al. Human anti-CD40 antagonist antibody triggers significant antitumor activity against humanmultiplemyeloma. Cancer Res. 2005;65(13):5898-5906. (Pubitemid 40911196)
14. Malmborg Hager AC, Ellmark P, Borrebaeck CA, et al. Affinity and epitope profiling of mouse anti- CD40 monoclonal antibodies. Scand J Immunol. 2003;57(6):517-524. (Pubitemid 36734991)
15. Pound JD, Challa A, Holder MJ, et al. Minimal cross-linking and epitope requirements for CD40- dependent suppression of apoptosis contrast with those for promotion of the cell cycle and homotypic adhesions in human B cells. Int Immunol. 1999;11(1):11-20. (Pubitemid 29037584)
16. Carpenter EL, Mick R, Ruter J, et al. Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation. J Transl Med. 2009;7:93.
17. Funakoshi S, Longo DL, Murphy WJ. Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20monoclonal antibodies against human B-cell lymphomas. J Immunother Emphasis Tumor Immunol. 1996;19(2):93-101. (Pubitemid 26139067)
18. Horton HM, Bernett MJ, Peipp M, et al. Fc-engineered anti-CD40 antibody enhancesmultiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies. Blood. 2010;116(16):3004- 3012.
19. Oflazoglu E, Stone IJ, Brown L, et al. Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40. Br J Cancer. 2009;100(1):113-117.
20. JundiM,NadiriA,Al-Zoobi L, et al. CD40-mediated cell deathrequiresTRAF6 recruitment.Immunobiology. 2011;217(3):375-383.
21. Law CL, Gordon KA, Collier J, et al. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res. 2005;65(18):8331-8338. (Pubitemid 41330598)
22. Vonderheide RH, Flaherty KT, Khalil M, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 2007;25(7):876-883. (Pubitemid 350002889)
23. Burington B, Yue P, Shi X, et al. CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma. Sci TranslMed. 2011;3(74):74ra22.
24. KalbasiA, Fonsatti E,Natali PG, et al.CD40 expression by humanmelanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893. J Immunother. 2010;33(8):810-816.
25. Lewis TS,McCormick RS, Emmerton K, et al. Distinct apoptotic signaling characteristics of the anti- CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma. Clin Cancer Res. 2011;17(14):4672-4681.
26. Francisco JA, Schreiber GJ, Comereski CR, et al. In vivo efficacy and toxicity of a single-chain immunotoxin targeted to CD40. Blood. 1997;89(12):4493-4500. (Pubitemid 27260259)
27. Chiodoni C, Paglia P, Stoppacciaro A, et al. Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response. J ExpMed. 1999;190(1):125-133. (Pubitemid 29330129)
28. Schattner EJ, Elkon KB, Yoo DH, et al. CD40 ligation induces Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway. J Exp Med. 1995;182(5):1557-1565.
29. Tai YT, Catley LP, Mitsiades CS, et al. Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res. 2004;64(8):2846-2852. (Pubitemid 38500624)
30. Hasbold J, Johnson-Leger C, Atkins CJ, et al. Properties of mouse CD40: cellular distribution of CD40 and B cell activation by monoclonal anti-mouse CD40 antibodies. Eur J Immunol. 1994;24(8):1835-1842. (Pubitemid 24237554)
31. Rolink A,Melchers F, Andersson J.The SCID but not the RAG-2 gene product is required for Smu-S epsilon heavy chain class switching. Immunity. 1996;5(4):319-330. (Pubitemid 26366755)
32. Johnson PW SN, Chowdhury F, et al. A Cancer Research UK phase I study evaluating safety, tolerability, and biological effects of chimeric anti-CD40 monoclonal antibody (MAb) Chi Lob 7/4. J Clin Oncol. 2010;28(15s):suppl; abstr 2507
33. Grangeon C, Cormary C, Douin-Echinard V, et al. In vivo induction of antitumor immunity and protection against tumor growth by injection of CD154-expressing tumor cells. Cancer GeneTher. 2002;9(3):282-288. (Pubitemid 34205503)
34. Tomihara K, Kato K, Masuta Y, et al. Gene transfer of the CD40-ligand to human dendritic cells induces NK-mediated antitumor effects against human carcinoma cells. Int J Cancer. 2007;120(7):1491-1498. (Pubitemid 46355383)
35. Carbone E, Ruggiero G, Terrazzano G, et al. A newmechanism of NK cell cytotoxicity activation: The CD40-CD40 ligand interaction. J ExpMed. 1997;185(12):2053-2060. (Pubitemid 27265988)
36. JyothiMD,Khar A. Regulation ofCD40L expression on natural killer cells by interleukin-12 and interferon gamma: its role in the elicitation of an effective antitumor immune response. Cancer Immunol Immunother. 2000;49(10):563-572.
37. Amakata Y, Fujiyama Y, Andoh A, et al. Mechanism of NK cell activation induced by coculture with dendritic cells derived fromperipheral blood monocytes. Clin Exp Immunol. 2001;124(2):214-222. (Pubitemid 32587605)
38. Atochina O, Harn D. LNFPIII/LeX-stimulated macrophages activate natural killer cells via CD40- CD40L interaction. Clin Diagn Lab Immunol. 2005;12(9):1041-1049. (Pubitemid 41324534)
39. Turner JG, Rakhmilevich AL, Burdelya L, et al. Anti-CD40 antibody induces antitumor and antimetastatic effects: The role of NK cells. J Immunol. 2001;166(1):89-94. (Pubitemid 32038420)
40. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol. 2010;22(2):231-237.
41. Dalton DK, Pitts-Meek S, Keshav S, et al.Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science. 1993;259(5102):1739-1742. (Pubitemid 23114658)
42. Schroder K, Hertzog PJ, Ravasi T, et al. Interferon-gamma: An overview of signals, mechanisms and functions. J Leukoc Biol. 2004;75(2):163-189. (Pubitemid 38174573)
43. Akira S, Sato S. Toll-like receptors and their signaling mechanisms. Scand J Infect Dis. 2003;35(9):555-562. (Pubitemid 37336872)
44. Klimp AH, de Vries EG, Scherphof GL, et al. A potential role of macrophage activation in the treatment of cancer. Crit Rev Oncol Hematol. 2002;44(2):143-161. (Pubitemid 36159043)
45. Urban JL, Shepard HM, Rothstein JL, et al. Tumor necrosis factor: A potent effector molecule for tumor cell killing by activatedmacrophages. Proc Natl Acad Sci U S A. 1986;83(14):5233-5237. (Pubitemid 16051349)
46. Hibbs JB, Jr., Taintor RR, Vavrin Z, et al. Nitric oxide: A cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun. 1988;157(1):87-94. (Pubitemid 19004828)
47. Griffith TS,Wiley SR,KubinMZ,et al.Monocyte-mediated tumoricidal activity via the tumornecrosis factor-related cytokine, TRAIL. J ExpMed. 1999;189(8):1343-1354.
48. Labeur MS, Roters B, Pers B, et al.Generation of tumor immunity by bonemarrow-derived dendritic cells correlates with dendritic cellmaturation stage. J Immunol. 1999;162(1):168-175. (Pubitemid 29018917)
49. Mackey MF, Gunn JR,Maliszewsky C, et al. Dendritic cells require maturation via CD40 to generate protective antitumor immunity. J Immunol. 1998;161(5):2094-2098. (Pubitemid 28397017)
50. Morse MA, Lyerly HK, Gilboa E, et al. Optimization of the sequence of antigen loading and CD40- ligand-inducedmaturation of dendritic cells. Cancer Res. 1998;58(14):2965-2968. (Pubitemid 28335071)
51. TschoepK,ManningTC,HarlinH, et al. Disparate functions ofimmature andmaturehumanmyeloid dendritic cells: implications for dendritic cell-based vaccines. J Leukoc Biol. 2003;74(1):69-80.
52. DeKruyff RH,Gieni RS,UmetsuDT. Antigen-driven but not lipopolysaccharide-driven IL-12 production inmacrophages requires triggering of CD40. J Immunol. 1997;158(1):359-366. (Pubitemid 127483877)
53. Alderson MR, Armitage RJ, Tough TW, et al. CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40. J Exp Med. 1993;178(2):669-674. (Pubitemid 23218216)
54. Imaizumi K, Kawabe T, Ichiyama S, et al. Enhancement of tumoricidal activity of alveolar macrophages via CD40-CD40 ligand interaction. Am J Physiol. 1999;277(1 Pt 1):L49-L57. (Pubitemid 29356750)
55. Buhtoiarov IN, Lum H, Berke G, et al. CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro. J Immunol. 2005;174(10):6013-6022. (Pubitemid 40663788)
56. Lum HD, Buhtoiarov IN, Schmidt BE, et al. Tumoristatic effects of anti-CD40 mAb-activated macrophages involve nitric oxide and tumour necrosis factor-alpha. Immunology. 2006;118(2): 261-270. (Pubitemid 43727432)
57. LumHD, Buhtoiarov IN, Schmidt BE, et al. In vivo CD40 ligation can induce T-cell-independent antitumor effects that involvemacrophages. J Leukoc Biol. 2006;79(6):1181-1192. (Pubitemid 44835552)
58. Rakhmilevich AL, Buhtoiarov IN, Malkovsky M, et al. CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors. Cancer Immunol Immunother. 2008;57(8):1151-1160.
59. Gao JJ, Diesl V,Wittmann T, et al. Bacterial LPS and CpG DNA differentially induce gene expression profiles inmousemacrophages. J Endotoxin Res. 2003;9(4):237-243. (Pubitemid 36874534)
60. Buhtoiarov IN, Lum HD, Berke G, et al. Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects. J Immunol. 2006;176(1):309-318. (Pubitemid 43023276)
61. Buhtoiarov IN, SondelPM,Eickhoff JC, et al.Macrophages are essential for antitumour effects against weakly immunogenic murine tumours induced by class B CpG-oligodeoxynucleotides. Immunology. 2007;120(3):412-423. (Pubitemid 46232916)
62. Stone GW, Barzee S, Snarsky V, et al. Regression of established AB1 murine mesothelioma induced by peritumoral injections ofCpGoligodeoxynucleotide either alone or in combinationwith poly(I:C) and CD40 ligand plasmid DNA. J Thorac Oncol. 2009;4(7):802-808.
63. Stone GW, Barzee S, Snarsky V, et al. Nanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-like receptor agonists as a treatment formelanoma. PLoS One. 2009;4(10):e7334.
64. Dye ES, North RJ. Macrophage accumulation in murine ascites tumors, I: cytoxan-induced dominance of macrophages over tumor cells and the anti-tumor effect of endotoxin. J Immunol. 1980;125(4):1650-1657. (Pubitemid 10018578)
65. Solomayer EF, Feuerer M, Bai L, et al. Influence of adjuvant hormone therapy and chemotherapy on the immune system analysed in the bone marrow of patients with breast cancer. Clin Cancer Res. 2003;9(1):174-180. (Pubitemid 36109730)
66. Johnson EE, Buhtoiarov IN, Baldeshwiler MJ, et al. Enhanced T-cell-independent antitumor effect of cyclophosphamide combined with anti-CD40 mAb and CpG in mice. J Immunother. 2011;34(1):76-84.
67. Buhtoiarov IN, Sondel PM, Wigginton JM, et al. Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages. Immunology. 2011;132(2):226-239.
68. Honeychurch J, Glennie MJ, Illidge TM. Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B cell lymphoma is dependent on CD11b+ cells. Cancer Res. 2005;65(16):7493-7501. (Pubitemid 41161285)
69. NowakAK, RobinsonBW, LakeRA. Synergy between chemotherapy andimmunotherapy in the treatment of establishedmurine solid tumors. Cancer Res. 2003;63(15):4490-4496. (Pubitemid 36951021)
70. Beatty GL, Chiorean EG, Fishman MP, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma inmice and humans. Science. 2011;331(6024):1612-1616.
71. Mantovani A, Allavena P, Sica A. Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. Eur J Cancer. 2004;40(11):1660-1667. (Pubitemid 38902900)
72. Guiducci C, Vicari AP, Sangaletti S, et al. Redirecting in vivo elicited tumor infiltratingmacrophages and dendritic cells towards tumor rejection. Cancer Res. 2005;65(8):3437-3446. (Pubitemid 40524630)
73. Li F, Ravetch JV. Inhibitory Fcgamma receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science. 2011;333(6045):1030-1034.
74. Li Q, Lao X, Pan Q, et al. Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression. Clin Cancer Res. 2011;17(15):4987-4995.
75. Jackaman C, Cornwall S, GrahamPT, et al. CD40-activated B cells contribute tomesothelioma tumor regression. Immunol Cell Biol. 2011;89(2):255-267.
76. Oehler L,Majdic O, PicklWF, et al.Neutrophil granulocyte-committed cells can be driven to acquire dendritic cell characteristics. J ExpMed. 1998;187(7):1019-1028. (Pubitemid 28176402)
77. Jackaman C, Lew AM, Zhan Y, et al. Deliberately provoking local inflammation drives tumors to become their own protective vaccine site. Int Immunol. 2008;20(11):1467-1479.
78. Mestas J, Hughes CC. Ofmice and notmen: differences between mouse and human immunology. J Immunol. 2004;172(5):2731-2738. (Pubitemid 38263654)
79. Hamzah J, Nelson D, Moldenhauer G, et al. Vascular targeting of anti-CD40 antibodies and IL- 2 into autochthonous tumors enhances immunotherapy in mice. J Clin Invest. 2008;118(5):1691-1699. (Pubitemid 351632373)
80. Hicks AM, Riedlinger G, Willingham MC, et al. Transferable anticancer innate immunity in spontaneous regression/complete resistancemice. Proc Natl Acad Sci U S A. 2006;103(20):7753-7758.
81. Broomfield SA, van der Most RG, Prosser AC, et al. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy. J Immunol. 2009;182(9):5217-5224.
82. Scarlett UK, Cubillos-Ruiz JR, Nesbeth YC, et al. In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. Cancer Res. 2009;69(18):7329-7337
83. Aranda F, Llopiz D,Diaz-Valdes N, et al. Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors. Cancer Res. 2011;71(9):3214-3224.
84. Uno T, Takeda K, Kojima Y, et al. Eradication of established tumors in mice by a combination antibody-based therapy. NatMed. 2006;12(6):693-698. (Pubitemid 43865240)
85. Pan PY,Ma G,Weber KJ, et al. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated bymyeloid-derived suppressor cells in cancer. Cancer Res. 2010;70(1):99-108.
86. Advani R, Forero-Torres A, Furman RR, et al. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol. 2009;27(26):4371-4377.
87. Hussein M, Berenson JR, Niesvizky R, et al. A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica. 2010;95(5):845-848.
88. Fransen MF, Sluijter M, Morreau H, et al. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin Cancer Res. 2011;17(8):2270-2280.
89. Malmstrom PU, Loskog AS, Lindqvist CA, et al. AdCD40L immunogene therapy for bladder carcinoma-The first phase I/IIa trial. Clin Cancer Res. 2010;16(12):3279-3287.